Nalaganje...
Expressions of MUC1 and vascular endothelial growth factor mRNA in blood are biomarkers for predicting efficacy of gefitinib treatment in non-small cell lung cancer
BACKGROUND: Gefitinib, an EGFR-tyrosine kinase inhibitor, significantly improve prognosis in patients with advanced non-small cell lung cancer (NSCLC). The aim of this study was to evaluate the usefulness of MUC1 and vascular endothelial growth factor (VEGF) mRNA expression in peripheral blood as me...
Shranjeno v:
| izdano v: | BMC Cancer |
|---|---|
| Main Authors: | , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
BioMed Central
2014
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4246503/ https://ncbi.nlm.nih.gov/pubmed/25410981 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-14-848 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|